{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:21:54Z","timestamp":1787718114119,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ero.2025.11.026","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:24:44Z","timestamp":1766755484000},"page":"46-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of drug levels as a biomarker in rheumatoid arthritis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-2224","authenticated-orcid":false,"given":"Hiroya","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2025.11.026_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ero.2025.11.026_bib0002","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Matteo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ero.2025.11.026_bib0003","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/rheumatology\/ket355","article-title":"Therapeutic drug monitoring in rheumatic diseases: utile or futile?","volume":"53","author":"Stamp","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.11.026_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2017.07.019","article-title":"Biomarkers as a treatment guide in rheumatoid arthritis","volume":"186","author":"Takeuchi","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ero.2025.11.026_bib0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and definition of surrogate endpoints. Preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol and Ther"},{"key":"10.1016\/j.ero.2025.11.026_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002216","article-title":"Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR point to consider","volume":"8","author":"Krieckaert","year":"2022","journal-title":"RMD open"},{"key":"10.1016\/j.ero.2025.11.026_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.026_bib0008","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bcp.15579","article-title":"A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis, and dermatitis","volume":"89","author":"Van de Meeberg","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ero.2025.11.026_bib0009","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/cpt.2974","article-title":"Methotrexate polyglutamates exposure-response modeling in a large cohort of rheumatoid arthritis patients starting methotrexate","volume":"114","author":"Heibing","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ero.2025.11.026_bib0010","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/S2665-9913(23)00070-X","article-title":"Reduced versus maximum tolerated methotrexate dose concomitant with tumor necrosis factor inhibitor in patients with rheumatoid arthritis (MIRACLE): a randomized, open-label, non-inferiority trial","volume":"5","author":"Tamai","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ero.2025.11.026_bib0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ard-2024-226350","article-title":"Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial","volume":"84","author":"Tamai","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.026_bib0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF\u03b1 NANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ero.2025.11.026_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152342","article-title":"The interest of therapeutic and pharmacological drug monitoring of methotrexate: a systematic review","volume":"52","author":"Chellal","year":"2025","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ero.2025.11.026_bib0014","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00228-024-03665-x","article-title":"Population pharmacokinetics analyses of methotrexate in pediatric patients: a systematic review","volume":"80","author":"Cheng","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ero.2025.11.026_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38414-0","article-title":"Pharmacokinetic-pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia","volume":"13","author":"Gebhard","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ero.2025.11.026_bib0016","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.026_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.026_bib0018","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ero.2025.11.026_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis: secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheum"},{"key":"10.1016\/j.ero.2025.11.026_bib0020","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","article-title":"Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dose escalation in rheumatoid arthritis","volume":"54","author":"Dervieux","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ero.2025.11.026_bib0021","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/rheumatology\/keq216","article-title":"Red blood cell methotrexate polyglutamates emerge as a function of dose intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.11.026_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD open"},{"key":"10.1016\/j.ero.2025.11.026_bib0023","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2013-203725","article-title":"Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis","volume":"74","author":"De Rotte","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.026_bib0024","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/mr\/roaf028","article-title":"1 mg\/day or 10 mg\/week? Folic acid supplementation with methotrexate in rheumatoid arthritis","volume":"35","author":"Tamai","year":"2025","journal-title":"Mod Rheum"},{"key":"10.1016\/j.ero.2025.11.026_bib0025","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease control in patients with chronic immune-mediated inflammatory disease","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ero.2025.11.026_bib0026","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease remission in patients with chronic immune-mediated inflammatory disease","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ero.2025.11.026_bib0027","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/art.42273","article-title":"Phase II\/III results of the anti-TNF multivalent NANOBODY\u00ae compound \u2018ozoralizumab\u2019 in patients with rheumatoid arthritis (OHZORA trial)","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ero.2025.11.026_bib0028","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jcph.2380","article-title":"Population pharmacokinetics of ozoralizumab in patients with rheumatoid arthritis","volume":"64","author":"Takeuchi","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ero.2025.11.026_bib0029","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","article-title":"25 years of biologic DMARDs in rheumatology","volume":"19","author":"Feldmann","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ero.2025.11.026_bib0030","doi-asserted-by":"crossref","first-page":"rkae030","DOI":"10.1093\/rap\/rkae030","article-title":"Overcoming provider barriers to therapeutic drug monitoring of tumor necrosis factor inhibitors in rheumatoid arthritis: a qualitative analysis","volume":"8","author":"Gavan","year":"2024","journal-title":"Rheum Adv Pract"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:53:38Z","timestamp":1787716418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125001260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050708125001260"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.026","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of drug levels as a biomarker in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}